Richard Lafayette, MD, Nephrology, Stanford, CA, Lucile Packard Children's Hospital Stanford

RichardAlanLafayetteMD

Nephrology Stanford, CA

Professor, Medicine - Nephrology, Stanford University Medical Center

Dr. Lafayette is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Lafayette's full profile

Already have an account?

Education & Training

  • Stanford University
    Stanford UniversityFELLOWSHIP
  • North Shore-Long Island Jewish Health System
    North Shore-Long Island Jewish Health SystemRESIDENCY
  • New York Medical College
    New York Medical CollegeMEDICAL_SCHOOL

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1988 - 2021
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Nephrology

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Facing the Vexing Problem of Recurrent FSGS After Kidney Transplantation
    Richard Lafayette, MD, American Society of Nephrology, Orlando, FL, 12/7/2019
  • Facing the Vexing Problem of Recurrent FSGS After Kidney Transplantation
    Richard Lafayette, MD, American Society of Nephrology, Orlando, FL, 12/7/2019

Press Mentions

  • Omeros Finalizes with FDA Clinical Plan for OMS721 Approval in IgA Nephropathy
    Omeros Finalizes with FDA Clinical Plan for OMS721 Approval in IgA NephropathyJanuary 17, 2019 21:17
  • Omeros Establishes Independent Academic Leadership Committee for Its OMS721 Phase 3 Clinical Program in IgA Nephropathy
    Omeros Establishes Independent Academic Leadership Committee for Its OMS721 Phase 3 Clinical Program in IgA NephropathyJanuary 13, 2019 08:20

Grant Support

  • Oral Calcimimetic Agent In Secondary HyperparathyroidismNational Center For Research Resources2000–2001

Hospital Affiliations